Shelly Odom, MD
Family Medicine · Morehead City, NCNPI 1245598929
Payments from drug & device makers
Across 315 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$934
- GSK$526
- Novo Nordisk$513
- Abbott$455
- Amgen$336
- Lilly USA, LLC$330
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,895100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $934 |
| GSK | 38 | $526 |
| Novo Nordisk | 37 | $513 |
| Abbott | 20 | $455 |
| Amgen | 23 | $336 |
| Lilly USA, LLC | 25 | $330 |
| Pfizer | 18 | $251 |
| Sanofi-aventis U.S. LLC | 10 | $171 |
| Merck | 10 | $158 |
| Angiodynamics, Inc. | 1 | $104 |
| AstraZeneca | 7 | $100 |
| Bayer | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Boehringer Ingelheim | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Astellas Pharma US Inc | 4 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Lundbeck LLC | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Johnson & Johnson | 3 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $31 |
| Novartis | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Si-bone, Inc. | 1 | $22 |
| Globus Medical | 1 | $22 |
| Cequr Corporation | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,895 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $132,540 |
| JardianceEmpagliflozin | 87 | $102,609 |
| TrulicityDulaglutide | 69 | $72,058 |
| RybelsusSemaglutide | 45 | $71,556 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $63,809 |
| EliquisApixaban | 63 | $50,781 |
| MounjaroTirzepatide | 36 | $37,580 |
| XareltoRivaroxaban | 31 | $30,259 |
| Repatha SureclickEvolocumab | 42 | $24,695 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $23,947 |
| Repatha SyringeEvolocumab | 21 | $21,053 |
| RexultiBrexpiprazole | 15 | $19,466 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $17,590 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,264 |
| MyrbetriqMirabegron | 12 | $16,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $513 | $204,096172 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $330 | $109,638105 claims |
| Boehringer IngelheimJardiance | $88 | $102,60987 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $526 | $92,235162 claims |
| PfizerEliquis | $251 | $50,78163 claims |
| Johnson & JohnsonXarelto | $37 | $30,25931 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $70 | $19,46615 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $171 | $17,59023 claims |
| AbbVieLinzess, Synthroid | $934 | $17,20465 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $16,09212 claims |
| MerckBelsomra | $158 | $7,32517 claims |
| AstraZenecaBreztri Aerosphere | $100 | $6,99711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Morehead City
- Ku Lang ChangMorehead City$153K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.